18 years of age or older
Item
18 years of age or older.
boolean
C0001779 (UMLS CUI [1])
confirmed adenocarcinoma of prostate (metastatic, hormonerefractory, clinically progressive)
Item
histologically or cytologically confirmed adenocarcinoma of prostate that is metastatic, hormone-refractory (confirmed by testing serum testosterone), and clinically progressive following at least one prior hormonal regimen.
boolean
C0007112 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C1328504 (UMLS CUI [1,3])
C0677932 (UMLS CUI [1,4])
progression on previous anti-androgen therapy
Item
patients must have documented progression of disease on anti-androgen withdrawal, if the patient have documented progression on previous anti-androgen therapy.
boolean
C0677932 (UMLS CUI [1,1])
C0279492 (UMLS CUI [1,2])
measurable disease or evaluable disease
Item
measurable (patient with measurable bi-dimensional disease) or evaluable disease (defined as the presence of a nonmeasurable abnormality on ct or on physical examination coupled with a psa ³ 30).
boolean
C1513041 (UMLS CUI [1])
C1516986 (UMLS CUI [2])
karnofsky performance status
Item
karnofsky performance status ³ 60%.6. adequate bone marrow functions: granulocyte count 1,000/mm3, platelets 75,000/mm3, haemoglobin 8 g/dl.
boolean
C0206065 (UMLS CUI [1])
creatinine, bilirubine, alt/ast measurement
Item
adequate renal and liver functions: creatinine < 1.5 mg/dl, bilirubin < 2 mg/dl, alt/ast less than 2.5 times the upper limit of the reference range for the institute.
boolean
C0201975 (UMLS CUI [1,1])
C0344395 (UMLS CUI [1,2])
C0201836 (UMLS CUI [1,3])
C0201899 (UMLS CUI [1,4])
thyroid replacement
Item
patients with chemical or clinical hypothyroidism should have their thyroid replacement prior to starting study.
boolean
C2242640 (UMLS CUI [1])
from the effect of recent surgery
Item
patients must have recovered from the effect of recent surgery (at least 4 weeks apart), radiotherapy (at least 4 weeks apart).
boolean
C2004454 (UMLS CUI [1,1])
C2169607 (UMLS CUI [1,2])
ability to complete quality of life questionnaires
Item
patients have ability to complete quality of life (qol) questionnaires.
boolean
C1321605 (UMLS CUI [1])
informed consent
Item
patients must sign informed consent.
boolean
C0021430 (UMLS CUI [1])
advanced second primary malignancy
Item
patients with advanced second primary malignancy.
boolean
C0751623 (UMLS CUI [1,1])
C0679246 (UMLS CUI [1,2])
patients with brain metastases
Item
patients with brain metastases.
boolean
C0220650 (UMLS CUI [1])
patients with hypersensitivity to thalidomide
Item
patients with hypersensitivity to thalidomide.
boolean
C0020517 (UMLS CUI [1,1])
C0039736 (UMLS CUI [1,2])
history of myocardial infarction, uncontrolled congestive heart failure or angina pectoris.
Item
history of myocardial infarction within past 6 months, uncontrolled congestive heart failure or angina pectoris.
boolean
C0027051 (UMLS CUI [1])
C0742746 (UMLS CUI [2])
C0002962 (UMLS CUI [3])
patients with orthostatic hypotension before therapy
Item
patients with orthostatic hypotension before therapy.
boolean
C0020651 (UMLS CUI [1])
nci grade or peripheral neuropathy
Item
patients with nci ctc grade 3 or greater peripheral neuropathy of any cause that is clinically detectable.
boolean
C3887242 (UMLS CUI [1])
C0031117 (UMLS CUI [2])
active infection, including positive serology for hiv
Item
patients with active infection, including positive serology for hiv.
boolean
C0009450 (UMLS CUI [1])
C0019693 (UMLS CUI [2])
prior chemotherapy
Item
patients who have received chemotherapy before for treatment of metastases of prostate cancer, or received other investigational agents or corticosteroids within 4 weeks prior to enrollment of study.
boolean
C1514457 (UMLS CUI [1])